

SOLIGENIX, INC.
Form 8-K
October 01, 2009

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): September 30, 2009

Commission File No. 000-16929

Soligenix, Inc.

(Exact name of small business issuer as specified in its charter)

DELAWARE

(State or other jurisdiction of incorporation
or organization)

41-1505029

(I.R.S. Employer Identification Number)

29 Emmons Drive,
Suite C-10
Princeton, NJ

(Address of principal executive offices)

08540

(Zip Code)

(609) 538-8200

(Issuer's telephone number, including area code)

DOR BioPharma, Inc.

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

On September 28, 2009, DOR Biopharma, Inc. filed an amendment to its Amended and Restated Certificate of Incorporation with the Delaware Secretary of State's Office changing its name to Soligenix, Inc. (the "Company"). On September 30, 2009 and as a result of the name change, the Company's shares of common stock began trading under the new ticker symbol "SNGX".

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Title
3.1	Amendment to Amended and Restated Certificate of Incorporation, dated September 28, 2009.
99.1	Press release issued by the Company on September 30, 2009.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Soligenix, Inc.

September 30, 2009 by: / s / C h r i s t o p h e r J .
Schaber
Christopher J. Schaber, Ph.D.
President and Chief Executive Officer
(Principal Executive Officer)

EXHIBIT INDEX

Exhibit No.	Title
3.1	Amendment to Amended and Restated Certificate of Incorporation, dated September 28,

2009.

99.1

Press release issued by the Company on
September 30, 2009.